SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler shares plummeted following a fiscal third-quarter earnings report that featured a guidance miss, leading to concerns over decelerating growth and increased capital expenditure. The community is sharply divided between investors panicking over management's narrative and leadership changes, and those attempting to buy the dip, with many debating if the company's valuation still holds as growth slows.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine is trending as investors react to a positive earnings double-beat, strong guidance for fiscal year 2027, and a new strategic partnership with Databricks to bolster AI capabilities. The community is actively debating the company's turnaround potential, focusing on debt management and high short interest versus the firm's growth in mobile advertising and AI-driven infrastructure.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is surging after reaching a historic trillion-dollar market cap, fueled by an aggressive UBS price target hike and intensifying optimism surrounding the company's role as a critical AI infrastructure and memory supplier. While bulls are celebrating the massive year-to-date rally and potential for further gains, the community remains intensely divided between those betting on continued parabolic growth and others cautioning that the stock has become dangerously overheated.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing significant volatility and increased interest driven by a combination of a technically oversold chart structure and speculative momentum regarding the company's Matrix-M adjuvant platform's potential use in emerging disease outbreaks. Community discourse is sharply divided between retail investors betting on a short squeeze or buyout potential and those frustrated by the company's leadership and persistent lack of clear communication regarding pipeline execution.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors aggressively monitor the approaching 80th clinical trial event for its lead AML therapy, with the community intensely debating the company's data transparency and the potential for a transformative buyout. Enthusiastic supporters are pointing to recent executive messaging and institutional interest as signals of a major valuation shift, while vocal skeptics maintain caution regarding trial outcomes and historical transparency.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing significant upward momentum as investors highlight a textbook short squeeze setup characterized by extremely high short interest, a shrinking free float due to active buybacks, and significant dealer hedging activity around key strike prices. Community sentiment is overwhelmingly bullish, with traders drawing parallels to historic short squeezes and actively discussing the potential for a parabolic move as they aim to force institutional shorts to cover their positions.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are actively debating the sustainability of the semiconductor sector's parabolic rally, with many retail traders experiencing significant losses while attempting to time a correction using the inverse leveraged ETF. The intense volatility and rapid price erosion of the symbol have sparked heated discussions about whether the industry is in a historic bubble or if the trend will continue to punish contrarian bets.

Sidus Space, Inc. is a space-as-a-service company. The firm focuses on commercial satellite design, manufacture, launch planning, mission operations and in-orbit support, and data collection with a vision to demonstrate space operations for new technologies, and deliver data and predictive analytics to both domestic and global customers. The company was founded by Carol M. Craig on July 17, 2012 and is headquartered in Merritt Island, FL.

Sidus Space Inc - Ordinary Shares - Class A

Sidus Space is trending as investors aggressively build positions in aerospace stocks ahead of the anticipated SpaceX IPO, with the community actively tracking its inclusion in the Russell 3000 and ongoing defense contract momentum. Sentiment remains highly bullish among long-term holders who are ignoring short-term volatility, while traders continue to focus on key technical breakouts and potential institutional accumulation.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is trending as retail traders drive momentum around the companys role in critical space infrastructure and NASA project participation, further fueled by anticipation surrounding the upcoming SpaceX IPO. The community is actively debating the potential for a short squeeze, with many long-term investors holding through volatility while others discuss profit-taking strategies and the broader re-rating of the aerospace sector.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific stock is under pressure as investors react to the company's agreement to acquire Penumbra for approximately $14.5 billion. While the community recognizes the strategic long-term value of expanding into the vascular and neurovascular markets, the immediate drop reflects concerns regarding the deal's size, potential dilution, and integration costs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock

Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock PR Newswire WASHINGTON, May 22, 2026 WASHINGTON, May 22, 2026...

LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT

LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT PR Newswire SACRAMENTO, Calif., May 20, 2026 SACRAMENTO, Calif., May 20, 2026 /PRNewswire/ --Lunai Bioworks, Inc. (Nasdaq: LNAI) (the "Company") today announced that it will effect a reverse stock...

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and...

Stock Market Today: Dow Jones, S&P 500 Futures Edge Lower Amid Extension Of Israel-Lebanon Ceasefire Intel, SAP, Lunai Bioworks In Focus

U.S. stock futures were mixed on Friday following Thursday's decline, after President Donald Trump announced the extension of the ceasefire between Israel and Lebanon by three weeks. On Thursday, the...

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient...

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under...

AI, Biotech, and Defense Converge: Small Caps Chase Big Markets as Innovation Narrative Heats Up

Today's top stocks include $LNAI, $HCTI, $TGNT, $KOD, $NAVN, $BTBD

Lunai Bioworks Unveils AI-Driven National Consortium to Fast-Track Chemical Defense Countermeasures

Lunai Bioworks (NASDAQ:LNAI) launched a new national consortium aimed at transforming how the United States develops medical countermeasures against emerging chemical threats. Operating through its subsidiary BioSymetrics, the company introduced the Pathfinder Consortium, an academic-industry alliance designed to unify historically fragmented chemical defense efforts across government, academia, and biotech into a single, execution-focused platform.

Why Did LNAI Stock Surge Over 25% Today? 

Equity

Lunai is acquiring $20 million in blood-brain barrier delivery tech and Alzheimer’s assets from Clemann Group.

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS...

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

LNAI
Lunai Bioworks Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest LNAI News

LNAILunai Bioworks Inc.